Abiopharma

Sana Biotechnology Inc (SANA) Reports Q3 2022 Financial Results Sana Biotechnology Inc (SANA) announced its financial results for the period ending Q3 2022. Key Financial Highlights:

• Revenue: Not disclosed
• Net Income: (0.39
• EPS: Not disclosed
• Cash and equivalents: (155,387
  • “We are pleased with the continued progress this quarter both across our platforms and with our product candidates. We made executive hires in critical operational roles, executed on key pre
  • IND activities for both SC291 and SG295, made business decisions that extend our cash runway to allow more potential clinical data readouts across multiple drug candidates with our current balance sheet, and presented important preclinical data across multiple platforms at various scientific conferences,” said Steve Harr, Sana’s President and Chief Executive Officer. “We are well
  • positioned with our current resources to file INDs across several platforms with multiple drug products in both 2022 and 2023, and our team is enthusiastic to understand the potential of these medicines to improve outcomes for patients.” Continued progress in building Sana’s hypoimmune ex vivo platform and in vivo fusogen platform with presentations at AACR, ASGCT, ADA, and ISSCR
    • expected in 2024